Nabta Health

Company profile

Nabta Health company profile

Nabta’s unique model of hybrid healthcare seamlessly combines digital health with traditional healthcare to improve health outcomes in women living with NCDs. The growing epidemic of NCDs threatens the ambition of countries around the world to achieve sustainable, universal access to health and universal health coverage for their populations. Moreover, NCDs leave populations more susceptible to communicable diseases such as coronaviruses, influenza and tuberculosis. During the COVID-19 pandemic of 2020, 78% of people admitted to ICU in the US and 94% of those who died had underlying health conditions (CDC). NCDs remain underesearched and underserved in women. Until the mid-1990s, clinical research and clinical trials largely excluded women. Only since 1994, when the United States’ National Institutes of Health (NIH) mandated that women and minorities were to be included as subjects in clinical research, has the research community entertained the fact that sex and/or gender differences might affect clinical outcomes. Today, women using drugs that were approved by the early 90s, are 50–75% more likely than men to suffer adverse reactions to those therapies. Ironically, a significant proportion of the drugs in this category are those designed to treat or manage NCDs. Examples include statins and potassium channel-blockers used to manage cardiovascular disease or hypoglycaemic drugs such as Rezulin used to control diabetes. Nabta’s first hybrid care pathway supports women in preventing, identifying and managing Polycystic Ovary Syndrome (PCOS). PCOS is a hormonal disorder responsible for 70% of female fertility issues. Women who use Nabta’s platform will be able to achieve a formal diagnosis of PCOS within 90 days. The average time taken to diagnose PCOS currently is 2.5 years.